MOGAMULIZUMAB

Brand name:

• Poteligeo

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Kyowa Kirin Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Cutaneous T-cell lymphoma

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (Matter arising from the minutes)

Comment:

--

Other PBAC consideration:

• MOGAMULIZUMAB
• MOGAMULIZUMAB

Submission received for:

September 2025 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 05/09/2025

PBAC outcome published:

Advice Provided (see PBAC Outcomes)

Lodgement of required documentation:

13/11/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 10/12/2025

Status:

Finalised

Government processes:

Commenced on 17/12/2025

Medicine listed on the PBS:

01/04/2026 (see PBS schedule)